Halozyme Therapeutics, Inc. (HALO) 2017年年度报告「NASDAQ」.pdf

1、PRODUCT PIPELINEPRODUCT,COLLABORATION PRODUCTS AND PRODUCT CANDIDATESRocheRoche (Total of 9 potential targets)BaxaltaJanssen (Total of 5 potential targets)OncologyPancreas CancerPhase 3HYLENEX recombinant(hyaluronidase human injection)VariousAdjuvant for subcutaneous fluid delivery for dispersion&ab

2、sorption of other injected drugs U.S.ApprovedMABTHERA SC(rituximab)(Outside of the U.S.)RITUXAN HYCELA (rituximab/hyaluronidase human)(U.S.)OncologyOncologyMultiple blood CancersMultiple blood CancersEU approved and other countries outside U.S.U.S.approvedHERCEPTIN SC(trastuzumab)OncologyBreast Canc

3、er EU approved and other countries outside U.S.PERJETA (pertuzumab)OncologyBreast CancerPhase 1(Plans for Phase 3 fixed-dose combination with Herceptin in 2018)Phase 1DARZALEX(daratumumab)OncologyAmyloidosis Smoldering Myeloma Multiple Myeloma(2L+)Multiple Myeloma(4L)Multiple Myeloma(1L+)Multiple My

4、eloma(3L+)Phase 3 Phase 3 Phase 3 Phase 3 Phase 2 Phase 1Lilly (Total of 5 potential targets)UndisclosedPhase 1Alexion (Total of 4 potential targets)ALXN1210 SCVariousPreclinicalTHERAPEUTIC AREARESEARCH FOCUS/INDICATION(PARTNER)DEVELOPMENT STAGEOncology Pipeline and Product CandidatesProprietary App

5、roved ProductENHANZE Collaboration Approved ProductsENHANZE Collaboration Product CandidatesImmunologyPrimary ImmunodeficiencyApproved for adults in the EU,U.S.,Puerto Rico and Australia;Pediatric indication approved in EUHYQVIA Immune Globulin Infusion 10%(Human)with Recombinant Human Hyaluronidase

6、 PEGPH20 with ABRAXANE (nab-paclitaxel)and gemcitabineOncologyGastric Cancer/Non-Small Cell Lung CancerPhase 1PEGPH20 with KEYTRUDA(pembrolizumab)OncologyPancreas Cancer(Genentech)Phase 1PEGPH20 with TECENTRIQ (atezolizumab)OncologyGastric Cancer(Genentech)Phase 1PEGPH20 with TECENTRIQ (atezolizumab